Compare Synopsys, Inc. (SNPS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs 10X Genomics Inc — how do they compare? Synopsys, Inc. trades at $502 (market cap $96.33B), while 10X Genomics Inc trades at $80.1 (market cap $9.92B). The key difference: Synopsys, Inc. is far larger — about 9.7× 10X Genomics Inc's market cap, and 10X Genomics Inc is more actively traded (9,372,166 versus 1,631,837). Which is the better fit depends on your goals — on Pluang, investors hold Synopsys, Inc. for 71 Days and 10X Genomics Inc for 92 Days on average.
| SNPS | TXG | |
|---|---|---|
Market Cap | $96.33B | $9.92B |
Volume | 1,631,837 | 9,372,166 |
Sector | Technology | Health |
52-Week High | $534.56 | $97.74 |
52-Week Low | $367.70 | $11.48 |
Typical Hold Time | 71 Days | 92 Days |
Enterprise Value | $103.56B | $9.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $497.75, down 1.47% on the day but remains near recent highs following strong quarterly earnings beats and bullish investor sentiment driven by AI partnerships. The stock shows a bullish technical trend with moving averages supporting upside, while RSI levels indicate overbought conditions. Recent news highlights multi-year agreements with OpenAI and Amazon Web Services, fueling growth expectations beyond traditional EDA markets.
The outlook is positive with a consensus price target of $572.54, reflecting 15% upside potential, though high valuation multiples (P/E of 87.73) and integration risks from the Ansys acquisition warrant caution. Revenue growth is projected to accelerate, supported by AI-driven demand, but margin compression and competitive pressures pose medium-term risks.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
